From the publishers of JADPRO

Myelofibrosis Resource Center

Advertisement
FROM THE EDITORS

Welcome to the new Myelofibrosis Resource Center! Here you’ll find current information, highlights from the literature, case studies, and other resources that focus on myelofibrosis and the advanced practitioner’s role in delivering high-quality care to patients.

                                   

Kate Kennedy, MSN, APRN, ACNP-BC, AOCNP®

Vanderbilt University Medical Center

Sarah Profitt, PharmD, MMHC, BCOP

Vanderbilt University Medical Center

News & Literature Highlights

European Journal of Haematology

Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine

American Journal of Hematology

Impact of donor type on outcomes after allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT

Journal of Hematology

Efficacy and safety of momelotinib in myelofibrosis: A systematic review and meta-analysis with a focus on anemia outcomes

Transplantation and Cellular Therapy

Risk stratification using DIPSS and splenomegaly in myelofibrosis treated with pre-transplant JAK inhibitors

International Journal of Hematology

Efficacy and safety of momelotinib in Janus kinase inhibitor experienced Asian patients with myelofibrosis and anemia

Clinical Lymphoma, Myeloma & Leukemia

Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: A retrospective cohort study

Journal of Inflammation Research

Prognostic implications of red blood cell distribution width to albumin ratio in myelofibrosis: A 10 year multicenter and retrospective study

Acta Haematologica

Impact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP studyImpact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP study

Indian Journal of Hematology and Blood Transfusion

Renal impairment in myeloproliferative neoplasms: An under-reported complication

European Journal of Haematology

Time without transfusion reliance (TWiTR): Integrating survival quality into myelofibrosis treatment strategies based on the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials

Advertisement
Advertisement